relatlimab

Overview

Relatlimab is an anti-LAG-3 monoclonal antibody targeting LAG3. It is evaluated in combination with nivolumab in nasopharyngeal carcinoma (NPC) in the randomized REMAIN trial.

Evidence in the corpus

• Relatlimab + nivolumab evaluated in the randomized REMAIN trial for LAG-3 co-blockade in NPC; LAG3 is an inhibitory receptor on exhausted T cells that is compensatorily upregulated following PD-1/PD-L1 monotherapy PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.